Canada Buys More SpikeVax Vaccines

The Honourable Anita Anand, Minister of Public Services and Procurement, announced on August 13, 2021, that Canada has entered into an agreement with Moderna for an additional supply of its SpikeVax COVID-19 vaccine for 2022 and 2023, with an option to extend into 2024.

The agreement guarantees 40 million mRNA vaccine doses, with access to up to 65 million more if all options are exercised.

Moreover, this agreement empowers access to new COVID-19 vaccine adaptations (coronavirus variants) based on the evolution of the epidemiological situation in Canada.

“Our government is continuing to work with leading vaccine developers to ensure that Canadians have ongoing access to a diverse portfolio of vaccines. This agreement will help to bridge Canada’s capacity to maintain a reliable and rapidly available supply of vaccines into 2022 and 2023 ahead of Moderna’s Canadian vaccine facility becoming operational," stated Minister Anand in a press statement.

The Government of Canada confirmed it would continue to follow scientific and expert advice to pursue future access to COVID-19 vaccines.

Moderna's SpikeVax COVID-19 mRNA vaccine was authorized for use by Health Canada on December 23, 2020, and is currently in use for people aged 12 and older.

Note: The number of COVID-19 cases (last 7 days) in Canada was 12,150 as of August 13, 2021.